Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.

PURPOSE OF REVIEW The improved understanding of the complex biochemical and genetic pathways associated with renal-cell carcinoma (RCC) has led to rapid development of novel targeted therapies over the last decade. The aim of this review is to present and discuss the most recent clinical trial data that support the currently approved first and second line… CONTINUE READING